Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
45
DNLI Quote, Financials, Valuation and Earnings
Last price:
$17.01
Seasonality move
:
-13.05%
Day range:
$16.72 - $17.05
52-week range:
$10.57 - $24.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.62x
P/B ratio:
2.86x
Volume:
505K
Avg. volume:
1.6M
1-year change:
-18.79%
Market cap:
$2.7B
Revenue:
--
EPS (TTM):
-$2.91
Analysts' Opinion
-
Consensus RatingDenali Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 17 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $32.21, Denali Therapeutics, Inc. has an estimated upside of 89.61% from its current price of $16.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $24.00 representing 100% downside risk from its current price of $16.99.
Fair Value
-
According to the consensus of 17 analysts, Denali Therapeutics, Inc. has 89.61% upside to fair value with a price target of $32.21 per share.
DNLI vs. S&P 500
-
Over the past 5 trading days, Denali Therapeutics, Inc. has underperformed the S&P 500 by -0.35% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Denali Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Denali Therapeutics, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Denali Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Denali Therapeutics, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Denali Therapeutics, Inc. reported earnings per share of -$0.74.
Enterprise value:
1.8B
EV / Invested capital:
1.91x
Price / LTM sales:
6.62x
EV / EBIT:
--
EV / Revenue:
3.00x
PEG ratio (5yr expected):
-1.10x
EV / Free cash flow:
-4.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$10.2M
Return On Assets:
-39.45%
Net Income Margin (TTM):
--
Return On Equity:
-44.34%
Return On Invested Capital:
-42.48%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $340.8M | -- | -- | -- | -- | |
| Gross Profit | $324.8M | -$8.1M | -$10.2M | -$1.8M | -$2.9M | |
| Operating Income | -$169.5M | -$504.6M | -$547.8M | -$123.2M | -$137.4M | |
| EBITDA | -$153.5M | -$496.5M | -$537.7M | -$121.3M | -$134.5M | |
| Diluted EPS | -$0.97 | -$2.76 | -$2.91 | -$0.63 | -$0.74 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1.1B | $1.1B | $868.8M | $882.6M | |
| Total Assets | $1.4B | $1.2B | $1.2B | $1.5B | $1.1B | |
| Current Liabilities | $54.3M | $360.7M | $71.2M | $87.1M | $90.1M | |
| Total Liabilities | $437.7M | $416.3M | $118.4M | $135.5M | $129.4M | |
| Total Equity | $1B | $811.3M | $1.1B | $1.3B | $926.2M | |
| Total Debt | $60M | $55M | $46.9M | $44.5M | $35.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$332M | -$362.6M | -$397.8M | -$59.1M | -$107.3M | |
| Cash From Investing | $48.7M | -$187.9M | $406.7M | $93.7M | $57.8M | |
| Cash From Financing | $312.8M | $493.2M | -$7.1M | -$18.6M | -$778K | |
| Free Cash Flow | -$347.6M | -$375.7M | -$410.8M | -$63M | -$105.9M | |
DNLI
Sector
Market Cap
$2.7B
$28.1M
Price % of 52-Week High
69.79%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-0.4%
-1.49%
1-Year Price Total Return
-18.79%
-17.13%
Beta (5-Year)
1.115
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$17.01
200-day SMA
Buy
Level
$15.06
Bollinger Bands (100)
Buy
Level
14.19 - 17.65
Chaikin Money Flow
Sell
Level
-15.9M
20-day SMA
Sell
Level
$18.11
Relative Strength Index (RSI14)
Sell
Level
45.62
ADX Line
Sell
Level
13.13
Williams %R
Buy
Level
-91.6456
50-day SMA
Sell
Level
$17.22
MACD (12, 26)
Sell
Level
-0.15
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-5.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.0972)
Sell
CA Score
(Annual)
Level (-0.4459)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.0734)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, DNLI has received 17 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DNLI average analyst price target in the past 3 months is $32.21.
-
Where Will Denali Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Denali Therapeutics, Inc. share price will rise to $32.21 per share over the next 12 months.
-
What Do Analysts Say About Denali Therapeutics, Inc.?
Analysts are divided on their view about Denali Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Denali Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $24.00.
-
What Is Denali Therapeutics, Inc.'s Price Target?
The price target for Denali Therapeutics, Inc. over the next 1-year time period is forecast to be $32.21 according to 17 Wall Street analysts, 17 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DNLI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Denali Therapeutics, Inc. is a Buy. 17 of 17 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DNLI?
You can purchase shares of Denali Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Denali Therapeutics, Inc. shares.
-
What Is The Denali Therapeutics, Inc. Share Price Today?
Denali Therapeutics, Inc. was last trading at $17.01 per share. This represents the most recent stock quote for Denali Therapeutics, Inc.. Yesterday, Denali Therapeutics, Inc. closed at $16.99 per share.
-
How To Buy Denali Therapeutics, Inc. Stock Online?
In order to purchase Denali Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get DNLI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DNLI
Sector
P/E ratio
--
23.89x
PEG ratio
-1.10x
-0.01x
P/B ratio
2.86x
1.81x
Price / LTM sales
6.62x
1.59x
Growth Metrics
DNLI
Sector
Revenue growth
--
4.62%
Earnings growth
-16.35%
11.06%
Revenue (5-year growth)
-100%
6.5%
Earnings forecast
-$0.76
-$0.21
Profitability
DNLI
Sector
Profitability FY 2024
-$7.8M
$3.6M
Return on invested capital
-42.48%
-31.84%
Return on assets
-39.45%
-27.96%
Return on equity
-44.34%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
5
Balance Sheet
DNLI
Sector
Total cash
$848.2M
$26.4M
Short term investments
$657.4M
$25.7M
Total assets
$1.4B
$76.9M
Long term debt
$35.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
87
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
60
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
